Patent EA-003131-B1 (EA)
Title: Ligands, including antibodies, showing reactivity against endocrine cells
IPC: C07K16/42
Filed: 1998-07-20
Abstract: 1.A polyclonal antibody, or its fragment, with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI. 2. A monoclonal antibody or its fragment with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI. 3. A peptide, which is not an anti-TCR Vbeta antibody, with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI, and having sequence SEQ ID NO: 2. 4. Nucleinic acid, encoding peptide according to claim 3, and having sequence SEQ ID NO: 1. 5. Vector comprising nucleinic acid according to claim 4. 6. Culture of eukaryotic host-cell, transformed by vector according to claim 5. 7. Culture of procariotic host-cell, transformed by vector according to claim 5. 8. Use of antibody according to claim 1 or 2, as a pharmaceutical or as a diagnostic agent. 9. Use of peptide according to claim 3, as a pharmaceutical or as a diagnostic agent. 10. Use of an antibody according to claim 1 or 2 in the manufacture of a medicament for the treatment of IDDM, NIDDM, or organ or non-organ specific autoimmune disease, cardiovascular disease, cancer cachexia and cancer or any other diseases where anti-phospholipid antibodies and/or hyperinsulinaemia and diseases and insulin resistance are present. 11. Use of polypeptide according to claim 3 in the manufacture of a medicament for the treatment of IDDM, NIDDM, or organ or non-organ specific autoimmune disease, cardiovascular disease, cancer cachexia and cancer or any other diseases where anti-phospholipid antibodies and/or hyperinsulinaemia and diseases and insulin resistance are present. 12. Composition comprising an effective amount of antibody according to claims 1 or 2, in conjunction with a acceptable carrier. 13. Composition comprising an effective amount of peptide according to claims 1 or 2, in conjunction with a acceptable carrier. 14. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of antibody according to claims 1 or 2. 15. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of peptide according to claims 3. 16. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of composition according to claim 12. 17. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of composition according to claim 13. 18. A method for detection of a naturally-occurring autoantibody in body fluid, comprising providing of contact of said body fluid with antibody according to claims 1 or 2 and with target molecules and assessing the amount of said autoantibody that binds specifically to the target molecule.